← Back to Search

Immunoregulatory and Regenerative Therapy

MRG-001 for COVID-19

Phase 2
Waitlist Available
Led By George Atiee, MD
Research Sponsored by MedRegen LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days
Awards & highlights

Study Summary

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Eligible Conditions
  • COVID-19
  • Coronavirus
  • Acute Respiratory Distress Syndrome
  • Stem Cells
  • Regeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and Tolerability
Secondary outcome measures
All-cause mortality assessed at 14, 28 and 60 days following randomization.
Change from baseline in ALT, AST, INR, Albumin, Bilirubin, LDH, BUN, eGFR
Change in Plerixafor concentration (ng/ml) from baseline in blood
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MRG-001Experimental Treatment1 Intervention
Multiple SC dose of 0.0066 mL/kg MRG-001 (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
Group II: PlaceboPlacebo Group1 Intervention
Single SC dose of 0.0066 mL/kg Sterile Injectable Saline (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.

Find a Location

Who is running the clinical trial?

ICON plcIndustry Sponsor
81 Previous Clinical Trials
25,174 Total Patients Enrolled
3 Trials studying COVID-19
487 Patients Enrolled for COVID-19
Johns Hopkins UniversityOTHER
2,266 Previous Clinical Trials
14,837,457 Total Patients Enrolled
34 Trials studying COVID-19
26,935 Patients Enrolled for COVID-19
MedRegen LLCLead Sponsor
4 Previous Clinical Trials
112 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
2021. "MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04646603.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top